Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Neuropace Inc (NPCE)

Neuropace Inc (NPCE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 482,633
  • Shares Outstanding, K 33,308
  • Annual Sales, $ 79,910 K
  • Annual Income, $ -27,140 K
  • EBIT $ -18 M
  • EBITDA $ -18 M
  • 60-Month Beta 1.85
  • Price/Sales 4.87
  • Price/Cash Flow N/A
  • Price/Book 25.81

Options Overview Details

View History
  • Implied Volatility 179.79% (+11.36%)
  • Historical Volatility 44.21%
  • IV Percentile 86%
  • IV Rank 63.51%
  • IV High 247.30% on 11/14/25
  • IV Low 62.31% on 05/19/25
  • Expected Move (DTE 28) 2.32 (16.18%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 4
  • Volume Avg (30-Day) 11
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 131
  • Open Int (30-Day) 162
  • Expected Range 12.02 to 16.66

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.14
  • Number of Estimates 3
  • High Estimate -0.10
  • Low Estimate -0.19
  • Prior Year -0.18
  • Growth Rate Est. (year over year) +22.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.02 +2.28%
on 02/12/26
17.44 -17.78%
on 01/22/26
-2.18 (-13.20%)
since 01/20/26
3-Month
13.28 +7.98%
on 11/21/25
17.90 -19.87%
on 01/13/26
+0.84 (+6.22%)
since 11/20/25
52-Week
7.56 +89.62%
on 08/13/25
18.98 -24.43%
on 05/21/25
+0.11 (+0.77%)
since 02/20/25

Most Recent Stories

More News
NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026

NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter of 2025...

NPCE : 14.34 (-1.04%)
NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook

-- Revenue expected to be approximately $100.0 million in FY 2025, representing growth of 25%-- --Revenue expected to be approximately $26.6 million in Q4 2025,...

NPCE : 14.34 (-1.04%)
NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference

NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 44th Annual J.P....

NPCE : 14.34 (-1.04%)
NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy

-- Submission supported by positive preliminary 18-month NAUTILUS data in patients with drug-resistant idiopathic generalized epilepsy (IGE) and generalized tonic-clonic (GTC) seizures --

NPCE : 14.34 (-1.04%)
NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy

-- First randomized controlled trial of neuromodulation in drug-resistant idiopathic generalized epilepsy (IGE) -- -- 18-month data show a 77% median reduction in generalized...

NPCE : 14.34 (-1.04%)
NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting

--Data presentations to feature 18-month NAUTILUS results and new Post Approval Study (PAS) analyses on GTC seizure reduction-- --RNS ® System...

NPCE : 14.34 (-1.04%)
NeuroPace Announces Favorable Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient Services

--Physician Fee Schedule (PFS) final rule substantially increases reimbursement for RNS neurostimulator implantation and replacement procedures-- --CY 2026 Outpatient...

NPCE : 14.34 (-1.04%)
NeuroPace Inc.: Q3 Earnings Snapshot

NeuroPace Inc.: Q3 Earnings Snapshot

NPCE : 14.34 (-1.04%)
NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

-- Reported record quarterly revenue of $27.4 million in Q3 2025 representing 30% growth -- -- Increased full-year 2025 revenue guidance to between $97 million and $98...

NPCE : 14.34 (-1.04%)
NeuroPace to Report Third Quarter 2025 Financial Results on November 4, 2025

NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter of 2025...

NPCE : 14.34 (-1.04%)

Business Summary

NeuroPace Inc. is a commercial-stage medical device company. It is focused on developing products to treat and transform the lives of patients suffering from epilepsy. NeuroPace Inc. is based in MOUNTAIN VIEW, Calif.

See More

Key Turning Points

3rd Resistance Point 14.93
2nd Resistance Point 14.79
1st Resistance Point 14.56
Last Price 14.34
1st Support Level 14.20
2nd Support Level 14.06
3rd Support Level 13.84

See More

52-Week High 18.98
Fibonacci 61.8% 14.62
Last Price 14.34
Fibonacci 50% 13.27
Fibonacci 38.2% 11.92
52-Week Low 7.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar